Royalty revenue growth - Company said the 48% year-over-year revenue increase was mainly due to 50% growth in royalty revenue from partner products launched since 2020, including VYVGART Hytrulo by Argenx and DARZALEX SC by Janssen.
New collaborations - Company said five new ENHANZE and Hypercon collaboration agreements signed year to date in 2026 expanded royalty revenue opportunity.
Product sales increase - Company said higher product sales contributed to overall revenue growth.
Key details and analyst view
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$481 million
$407.49 million (6 analysts)
Q2 Adjusted EPS
Beat
$2.28
$1.84 (5 analysts)
Q2 EPS
$1.90
Q2 Net Income
$229.90 million
Q2 Operating Income
$287.70 million
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for Halozyme Therapeutics, Inc. is $91.23, about 9.1% above its August 5 closing price of $83.59.
HALO•
